236 related articles for article (PubMed ID: 12434692)
1. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
Trotter CL; Ramsay ME; Kaczmarski EB
Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692
[TBL] [Abstract][Full Text] [Related]
2. Estimating the burden of serogroup C meningococcal disease in England and Wales.
Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
[TBL] [Abstract][Full Text] [Related]
3. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision.
Cano R; Larrauri A; Mateo S; Alcalá B; Salcedo C; Vázquez JA
Euro Surveill; 2004 Jul; 9(7):11-5. PubMed ID: 15318008
[TBL] [Abstract][Full Text] [Related]
4. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
De Wals P; Deceuninck G; Boulianne N; De Serres G
JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
[TBL] [Abstract][Full Text] [Related]
6. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
Trotter CL; Edmunds WJ
BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
[TBL] [Abstract][Full Text] [Related]
7. Enhanced surveillance scheme for suspected meningococcal disease in five regional health authorities in England: 1998.
Davison KL; Crowcroft NS; Ramsay ME; Begg NT; Kaczmarski EB; Stuart JM; White JM; Orr H;
Commun Dis Public Health; 2002 Sep; 5(3):205-12. PubMed ID: 12434690
[TBL] [Abstract][Full Text] [Related]
8. Investigating the aetiology of and evaluating the impact of the Men C vaccination programme on probable meningococcal disease in England and Wales.
Granerod J; Davison KL; Ramsay ME; Crowcroft NS
Epidemiol Infect; 2006 Oct; 134(5):1037-46. PubMed ID: 16492318
[TBL] [Abstract][Full Text] [Related]
9. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
[TBL] [Abstract][Full Text] [Related]
12. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
13. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.
Ladhani SN; Flood JS; Ramsay ME; Campbell H; Gray SJ; Kaczmarski EB; Mallard RH; Guiver M; Newbold LS; Borrow R
Vaccine; 2012 May; 30(24):3710-6. PubMed ID: 22429756
[TBL] [Abstract][Full Text] [Related]
14. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients].
de Greeff SC; de Melker HE; Spanjaard L; van den Hof S; Dankert J
Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1132-5. PubMed ID: 12822525
[TBL] [Abstract][Full Text] [Related]
15. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
[TBL] [Abstract][Full Text] [Related]
16. Changes in Meningococcal Strains in the Era of a Serogroup C Vaccination Campaign: Trends and Evolution in Belgium during the Period 1997-2012.
Mattheus W; Hanquet G; Collard JM; Vanhoof R; Bertrand S
PLoS One; 2015; 10(10):e0139615. PubMed ID: 26425857
[TBL] [Abstract][Full Text] [Related]
17. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
Mooney JD; Christie P; Robertson C; Clarke SC
Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
[TBL] [Abstract][Full Text] [Related]
18. Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.
Pascucci MG; Di Gregori V; Frasca G; Rucci P; Finarelli AC; Moschella L; Borrini BM; Cavrini F; Liguori G; Sambri V; Bonanni P; Fantini MP
Hum Vaccin Immunother; 2014; 10(3):671-6. PubMed ID: 24384537
[TBL] [Abstract][Full Text] [Related]
19. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine.
Salleras L; Domínguez A; Cardeñosa N
Vaccine; 2003 Jan; 21(7-8):729-33. PubMed ID: 12531350
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
